Vapotherm, a New Hampshire-based med tech company, has released the next generation of its capital unit: The Precision Flow Hi-VNI system. The system is used to deliver non-invasive ventilation to spontaneously breathing patients using the company’s Mask-Free NIV technology. For the new generation of the Precision Flow® system, both the hardware and software have been updated to improve reliability, and to comply with the EMC 4th Edition requirements for medical devices, IEC 60601-1-2:2014.
“We’re excited to offer this next generation of the Precision Flow system to our customers,” said Joe Army, CEO. “We remain dedicated to continuous improvement in the products and services we offer our customers and patients and these improvements deliver on that commitment.”
The Precision Flow Hi-VNI system was granted a new product category and product code (QAV) by the U.S. Food and Drug Administration (FDA) in 2018. The FDA also granted an expanded indication for the system that states it may be used to augment breathing of spontaneously breathing patients suffering from respiratory distress in a hospital setting. This patient population is similar to that treated by other forms of non-invasive ventilation, making the Precision Flow Hi-VNI system a viable alternative to Non-invasive Positive Pressure Ventilation (NiPPV) for most patients, said a press release.
Hi-VNI® Technology is mask-free noninvasive ventilation designed for spontaneously breathing patients and a front-line tool for relieving respiratory distress – including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one simple tool. Hi-VNI Technology’s mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies. While being treated, patients can talk, eat, drink and take medication.
Vapotherm develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 1.5 million patients have been treated with Vapotherm Hi-VNI Technology.